Chronic Pain Composition Merging SNRI and NSAID
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic pain and mixed pain sites require multiple medications, leading to potential errors in administration and inadequate pain management due to limitations such as delayed onset of action, side effects, and inadequate efficacy.
Innovation Solution
A composition comprising a serotonin and norepinephrine reuptake inhibitor, a non-steroidal anti-inflammatory agent, optionally acetaminophen, oxcarbamazepine, an oral opioid antagonist, an antacid, an anti-epileptic, and an opioid, administered in a therapeutically effective dosage to provide comprehensive pain relief.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If multiple separate medications are used to treat mixed pain sites, then pain management coverage is improved, but administration complexity and error risk increase
Solution Approach 1:
The patent combines multiple pain management medications (SNRI, NSAID, acetaminophen, oxcarbamazepine, opioid antagonist, antacid, anti-epileptic, and opioid) into a single composition that can be administered together. This merging approach maintains comprehensive pain management coverage while eliminating the complexity of administering and tracking multiple separate medications, directly resolving the technical contradiction between pain management versatility and administration complexity.
2Adaptability or versatility
If multiple separate medications are used to treat mixed pain sites, then pain management coverage is improved, but patient tracking burden increases
Solution Approach 1:
By consolidating multiple medications into a single composition, the patent eliminates the need for patients to track which medications have been taken, at what dosages, and when. This single administration form reduces information loss and tracking burden while preserving comprehensive pain management coverage through the synergistic combination of ingredients.
3Reliability
If conventional pain medications are used, then pain relief is achieved, but delayed onset of action and side effects occur
Solution Approach 1:
The patent incorporates an opioid antagonist and antacid as preliminary components that prepare the system for enhanced pain relief. The opioid antagonist pre-positioned in the composition can rapidly counteract opioid cravings and effects, while the antacid prepares the gastrointestinal system to reduce side effects. This preliminary action enables faster and more reliable pain relief while minimizing delays and adverse effects.
4Reliability
If opioid analgesics are used for chronic pain, then strong pain relief is achieved, but physiological and psychologic dependence develops
Solution Approach 1:
The patent converts the harmful dependence effect of opioids into a beneficial control mechanism by incorporating an opioid antagonist. The antagonist works in conjunction with the opioid to provide strong pain relief while simultaneously counteracting the dependence potential. This transforms the harmful factor (opioid dependence) into a beneficial control system that maintains pain relief strength while preventing physiological and psychologic dependence.
Data Source
AI summary
A composition for the treatment of chronic pain and mixed pain sites may include a serotonin and norepinephrine reuptake inhibitor; a non-steroidal anti-inflammatory agent; optionally acetaminophen; optionally oxcarbamazepine; optionally an oral opioid antagonist; optionally an antacid; optionally an anti-epileptic; and optionally an opioid. A method for treating chronic pain and mixed pain sites may include administering, to a patient in need, a therapeutically effective dosage of the composition.